Natalya P. Kotlukova

Natalya P. Kotlukova

Auto-generated profile, based on publicly available information

Natalya P. Kotlukova

Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
NKN. P. Kotlukova
N. P. Kotlukova
TBT. S. Belysheva
T. S. Belysheva
LSL. I. Shats
L. I. Shats
VFV. A. Fochenkova
V. A. Fochenkova
ECE. D. Chavpetsova
E. D. Chavpetsova
LZL. V. Zhivova
L. V. Zhivova
Introduction. Infantile hemangiomas (IH) are the most common benign vascular tumor of children of the first year and are an interdisciplinary problem of neonatologists, pediatricians, pediatric cardiologists, oncologists, pediatric surgeons, dermatologists. Depending on the age of child, phase of pathological process, size, and localization of the IH, the management tactics of such children can be conservative (pharmaceuticals therapy) or invasive (laser therapy, surgical methods). Laser therapy with a pulsed dye laser has proven itself well to correct and minimize residual phenomena because of spontaneous involution and after the completion of pharmaceuticals treatment.The purpose of the study is to analyze the experience of using Hemangiol® (oral solution) for the treatment of children with IH, obtained in 10 medical hospitals in 6 cities of Russia.Materials and methods. Treatment with Hemangiol® was carried out in 6 cities of Russia on the basis of 10 medical hospitals (Children’s CityClinical Hospital named after Z.A. Bashlyaeva of Moscow City Health Department, Research Institute of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia (Moscow), Russian Children’s Clinical Hospital of the N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia (Moscow), Children’s City Clinical Hospital named after N.F. Filatov of Moscow City Health Department, Saint Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological) (S.-Petersburg), Almazov National Medical Research Centre, Ministry of Health of Russia (S.-Petersburg), Rostov Regional Clinical Hospital (Rostov-on-Don), Stavropol Regional Children’s Clinical Hospital (Stavropol), Samara Regional Clinical Hospital named after V.D. Seredavin, Children’s Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan (Kazan) in the Departments of Pediatric Cardiology, Surgery, Oncology, Pediatrics from January 2020 to December 2021. Therapy with Hemangiol® was received by 49 children with IH for at least 3 months. Before the start of treatment, the patients’ heart rate and blood pressure were measured, general and biochemical blood tests were performed, electrocardiography and ultrasound IH were performed. According to the indications, ultrasound of the liver and thyroid gland was performed to determine the parameters of the thyroid status. Before the start of therapy and during dynamic observation, photo documentation was performed against the background of treatment. In the absence of contraindications to treatment, Hemangiol® was prescribed. During a six-month course of treatment with Hemangiol®, effectiveness was evaluated based on the results of a clinical examination and based on photographs. The appearance of possible adverse reactions was monitored.Results. In 33 (67.3 %) children with IH, therapy with Hemangiol® was completed within 6 months. The effect of treatment in the form of a pronounced regression of vascular tumor was achieved in 25 (75.8 %) of 33 patients. In 16 (32.7 %) of 49 children, treatment with Hemangiol® was continued for more than 6 months. The first symptoms of improvement were observed from the second to 10 days after the start of Hemangiol® therapy in 45 patients, which was (91.8 %). Rebound syndrome (recurrence of IH) was detected in 2 (6.0 %) of 33 children who completed therapy. Transit adverse reactions (decreased heart rate, increased excitability, lethargy) on therapy of Hemangiol® were observed in 8 (16.3 %) children. The duration of therapy with Hemangiol® depended on the prevalence, the depth of the IH lesion, as well as on the presence of prematurity in a child with IH (r = 0.533, p < 0.05). Successful laser treatment with a pulsed laser on a dye after the completion of systemic Hemangiol® therapy, were on 5 children of Research Institute of Pediatric Oncology and Hematology at N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia.Conclusion. The results of the using of Hemangiol® as a modern means of systemic pharmacotherapy of IH therapy in 10 medical hospitals in 6 cities of Russia have demonstrated its high efficiency and safety.

7 November 2021 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
TBTatyana S. Belysheva
Tatyana S. Belysheva
NKNatalya P. Kotlukova
Natalya P. Kotlukova
TVTimur Valiev
Timur Valiev
NKNataliya K. Konstantinova
Nataliya K. Konstantinova
NTNatalya D. Telezhnikova
Natalya D. Telezhnikova
LGLuiza R. Gazalieva
Luiza R. Gazalieva
Background. Infantile hemangiomas are revealed in 1-3% of newborns and 10-12% of infants. There are only anecdotal reports on the laser therapy efficacy in this pathology management. However, there is no common approach to the use of this method in the complex treatment of infantile hemangioma in infants. Clinical Cases Description. Two clinical cases of infantile hemangioma are presented. Patients underwent complex treatment: systemic propranolol and laser therapy via pulsed dye laser. Laser exposure modes ware selected individually: laser spot sizes were 10 and 12 mm, energy levels were 5-10 J/cm2, burst duration was short (0.45 ms) or long (10-20 ms), procedure duration was from 15 to 40 minutes, number of procedures varied from 1 to 8. Laser therapy has shown its efficacy in treatment of superficial infantile hemangioma. Conclusion. The indication for using laser therapy in management of infants with hemangiomas is especially persistent residual signs such as telangiectasias and erythema after spontaneous or drug involution phase. Laser therapy allows us to avoid aggressive methods and improves the quality of life of our patients according to this article.

28 May 2021 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
NKN.P. Kotlukova
N.P. Kotlukova
TBT.S. Belysheva
T.S. Belysheva
TVTimur Valiev
Timur Valiev
NKN.K. Konstantinova
N.K. Konstantinova
NTN.D. Telezhnikova
N.D. Telezhnikova
MHMoscow Z.A. Bashlyaeva Children’s City Clinical Hospital
Moscow Z.A. Bashlyaeva Children’s City Clinical Hospital
The aim of the study is to find the best approaches to the treatment of infantile hemangiomas (IH). Materials and methods of research: the experience of treatment of pediatric patients with IH of various localization is presented, which was carried out according to the protocol elaborated by the authors. Systemic therapy with propranolol, local therapy, laser therapy were used in the complex of treatment. The age of patients at the beginning of therapy ranged from 1 month up to 4,5 years. Results: in all cases, patients with propranolol treatment showed a quick and stable effect. Even at the time of the selection of the dose of the drug, IH patients began to involute, became paler, less tense. The thickness of the soft tissues in the IH area decreased by 65% compared to the baseline, the number of functioning vessels decreased by 86%. The maximum effect was achieved within the first 6 months from the start of therapy. Clinical case report – a 2,5-year-old child with extensive hemangioma of the right buttock. There was a complex treatment with propranolol, local therapy, laser therapy. The general course of treatment with propranolol was 2 years 8 months. The total number of laser interventions was 6 with the overall effect in the form of maximum regression of residual clinical manifestations of IH. A positive clinical and ultrasound picture was noted, indicating a pronounced involution of IH, and a gradual withdrawal of propranolol was started. Conclusion: the effectiveness of a comprehensive interdisciplinary approach to the treatment of extensive complicated IH was demonstrated with the participation of specialists of various disciplines: pediatricians, cardiologists, surgeons, specialists in functional and ultrasound diagnostics, specialists in laser therapy, endocrinologists in a severe premature baby with a large number of somatic problems. The clinical treatment algorithm developed and implemented for patients with IH makes it possible to avoid more aggressive methods of treatment of this pathology and to improve the quality of life of this category of patients. On the basis on the results obtained, indications for laser therapy with a selective pulsed laser were formulated.

18 February 2022 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
DODmitry Ovsyannikov
Dmitry Ovsyannikov
NKN.P. Kotlukova
N.P. Kotlukova
NTN.D. Telezhnikova
N.D. Telezhnikova
MHMoscow Z.A. Bashlyaeva Children’s City Clinical Hospital
Moscow Z.A. Bashlyaeva Children’s City Clinical Hospital
ITI.I. Trunina
I.I. Trunina
AFA.P. Fisenko
A.P. Fisenko
The article presents the first descriptions of observations in the Russian Federation, the difficult path to diagnosis in two young girls with diseases associated with mutations in the filamin A gene, characterized by damage to the central nervous system (periventricular nodular heterotopy), lungs (interstitial emphysematous lesion due to impaired growth), cardiovascular system (open arterial duct, high pulmonary hypertension, insufficiency of heart valves, large vessels). Clinical and anamnestic data, the results of laboratory and instrumental diagnostic methods, including molecular genetic ones, which allowed to identify unique, previously undescribed mutations, the characteristics of the course of the disease, the treatment being carried out, are presented.

25 February 2024 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
EVElena Vasichkina
Elena Vasichkina
LBLarisa A. Balykova
Larisa A. Balykova
EBElena N. Basargina
Elena N. Basargina
LBLiudmila V. Bregel
Liudmila V. Bregel
EDElena A. Degtyareva
Elena A. Degtyareva
ЛЯЛ. В. Яковлева
Л. В. Яковлева
Readers will be presented with a series of articles on myocarditis in children, which are based on clinical guidelines developed by a group of authors on this topic. Myocarditis is an inflammatory myocardial disease characterized by a wide range of clinical manifestations — from minor to sudden cardiac death. Given the absence of pathognomonic symptoms, as well as the similarity of manifestations in the onset with common childhood diseases such as respiratory distress, gastrointestinal diseases, infectious pathology, specialists often overlook the likelihood of a diagnosis of “myocarditis”, which causes a late start of therapy and an adverse outcome. Considering that myocarditis accounts for 12% of cases of sudden cardiac death in adolescents and young adults, suspicion of this disease in differential diagnosis in children with nonspecific symptoms and disease progression may be the key to the formation of a proper treatment strategy. Despite significant advances in the study of myocarditis in both adults and children, there are still many unresolved issues. The purpose of this article is to highlight the current view of the etiology, pathogenesis, epidemiology and clinical features in children with various types of myocarditis in order to increase the knowledge of practitioners for better clinical management of patients with myocarditis.

12 November 2024 in Russian Pediatric Journal
Verified
Journal Article
Open access
PDF file
EVElena Vasichkina
Elena Vasichkina
ЛБЛариса Александровна Балыкова
Лариса Александровна Балыкова
ЕБЕлена Николаевна Басаргина
Елена Николаевна Басаргина
LBLiudmila V. Bregel
Liudmila V. Bregel
EDElena A. Degtyareva
Elena A. Degtyareva
ЛЯЛюдмила Викторовна Яковлева
Людмила Викторовна Яковлева
Introduction. A review of the current literature on the features of the diagnosis of myocarditis in children is presented. Myocarditis is an acute or chronic inflammatory myocardial disease characterized by a variety of clinical manifestations, nonspecific symptoms and physical data. With insufficient number of informative diagnostic tests, there is a challenge for practitioners at all stages of medical care. Aim of the review is to comprehensively present the features of the clinical diagnosis of myocarditis in children. The presence of myocarditis should be assumed in situations where children, regardless of the age, first developed symptoms of heart failure (HF), as well as in the presence of a clinic of viral infections accompanied by respiratory or abdominal symptoms, combined with the development of tachycardia, hypotension or cardiac arrhythmias, even in the absence of cardiomegaly. Myocarditis should be clinically suspected at the stage when the necessary decisions should be made about the patient’s routing, the formation of a complex of diagnostic examinations and the start of therapy. Magnetic resonance imaging (MRI) of the heart is today the non-invasive gold standard for the diagnosis of myocarditis that allows detecting myocarditis within 2–3 weeks after the first symptoms appear. Endomyocardial biopsy can be used for accurate morphological diagnosis of myocarditis in children. Molecular biological and genetic studies that determine the severity and outcome of the disease are important for the diagnosis of myocarditis in children. Conclusion. Based on the literature data and own experience in diagnosing myocarditis, the authors have developed an original diagnostic algorithm to make the right medical decision in case of suspected acute myocarditis in children.